CDE Catalog

***Please contact the NINDS CDE Team (NINDSCDE@emmes.com) if you encounter any search difficulties.***

The CDE Catalog is a directory of the available NINDS CDEs. Users can search the Catalog to isolate a subset of the CDEs (e.g., all stroke-specific CDEs, etc.), and to view and download details about the CDEs.

Select any filter below to search the CDE Catalog.

For best results, clear form between searches. In addition, when specifying NeuroRehab, Sport-Related Concussion (SRC) or Traumatic Brain Injury (TBI) as the Disease, please select a Subdisease as well.

NeuroRehab Comprehensive includes all NeuroRehab CDE recommendations. NeuroRehab General includes all NeuroRehab CDE recommendations that are not disease specific. All other NeuroRehab Subdiseases include recommendations specific to existing NINDS CDE project disorders.

Choose your Time Frame for your SRC study (Acute (time of injury until 72 hours), Subacute (after 72 hours to 3 months), and Persistent/Chronic (3 months and greater post-concussion) or Comprehensive if your study falls across the study time frames.

Choose your type of TBI study (Acute Hospitalized, Concussion/Mild TBI, Moderate/Severe TBI: Rehabilitation, or Epidemiology) or Comprehensive if your study falls outside of the study types or incorporates aspects of more than one type of study.

Search Form

Displaying 476 - 500 of 675
Operations
Selected 25 rows in this page.  
The search results below can be downloaded by clicking the checkboxes on the far left side of the table. Select the header checkbox to select all CDEs listed on the first page. Then choose CDE Detailed Report from the Choose an operation dropdown menu.
CDE ID CDE Name Definition Classification CRF Name Copyrighted or trademarked Disease Name Subdisease Name
C12229 Tissue specimen size measurement

Measurement of the size of the tissue specimen collected

Core Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12524 Inflammation severity status

Severity of Inflammation muscle diagnostic abnormalities

Supplemental Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12525 Biopsy and autopsy fiber abnormality type

Fiber type abnormalities on a muscle biopsy

Core Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12240 Biochemical or genetic test performed indicator

Indicator of whether subsequent biochemical or genetic testing was performed

Supplemental Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C17899 Preservation technique not used indicator

Indicates preservation technique used is not known

Supplemental Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12251 Biopsy and autopsy atrophy or hypotrophy type

Atrophy/ hypertrophy type

Supplemental Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12259 Biopsy and autopsy inflammation type

Perivascular inflammation is focused around blood vessels, whereas diffuse inflammation also spreads across the muscle tissue. Inflammatory cells identified include lymphocytes, neutrophils, macrophages, and eosinophils. At times, microorganisms can be identified and should be mentioned

Supplemental Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12267 Biopsy and autopsy liver biopsy autopsy results

The results of the liver biopsy

Supplemental Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12275 Biopsy and autopsy absent immunoreactivity assay name

Absent immunoreactivity

Supplemental Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12230 Tissue specimen collection date and time

Date (and time if applicable and known) when the tissue specimen was collected

Core Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12526 Biopsy and autopsy type 1 predominance fiber percentage value

Percentage of Type 1 predominance fiber present

Supplemental-Highly Recommended Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12241 Biochemical or genetic test name

Name of the biochemical or genetic test as performed on the specimen

Supplemental Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C17900 Age presentation year value

Age (in years) of participant/subject at presentation

Supplemental Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12252 Biopsy and autopsy fiber size variation result type

Distribution of the atrophic fibers

Supplemental Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12260 Biopsy and autopsy perivascular inflammation type

Evidence of vascular damage includes damaged vessels in association with perivascular inflammation and the presence of fibrin thrombi located within vascular spaces

Supplemental Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12268 Immunohistochemical stain used muscle biopsy and autopsy type

Which immunohistochemical stains were used on muscle biopsy?

Supplemental Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12276 Biopsy and autopsy mitochondria abnormality type

Type of mitochondria abnormality in muscle biopsy

Supplemental Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12231 Laboratory name

Name of laboratory where assessment was performed

Supplemental Muscle Biopsy and Autopsy Tissue Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C19751 Gene mutation myotonic dystrophy repeat length assessment indicator

Indicator of whether the mutated repeated allele's length was analyzed

Supplemental Mutation Analysis Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C19759 Target RNA alternative splicing text

Text identifying the type of target RNA species were investigated and in which tissue

Supplemental Mutation Analysis Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12803 Gene variant mutation implications confirmed mRNA analysis indicator

Indicator of whether the messenger ribonucleic acid (mRNA) analysis confirmed implications of genetic analysis

Supplemental Mutation Analysis Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C19752 Gene mutation myotonic dystrophy repeat assessment count

Count of copy numbers of the mutated allele length

Supplemental Mutation Analysis Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12804 Gene cDNA variant mutation name

Name using the Human Genome Organisation (HUGO) variant or mutation nomenclature of the complementary deoxyribonucleic acid (cDNA) variant or mutation

Supplemental Mutation Analysis Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C19753 Gene mutation myotonic dystrophy repeat assessment length value

Length of the mutated allele

Supplemental Mutation Analysis Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
C12805 Gene mRNA variant mutation name

Name using the Human Genome Organisation (HUGO) variant or mutation nomenclature of the messenger ribonucleic acid (mRNA) variant or mutation

Supplemental Mutation Analysis Myotonic Muscular Dystrophy Myotonic Muscular Dystrophy
Displaying 476 - 500 of 675

The NINDS CDE Team does not post proprietary instruments/scales recommended by the CDE Working Groups on this website. This includes, but is not limited to, copyrighted or trademarked instruments/scales. Information about recommended instruments can be found in the Notice of Copyright (NOC) documents under ‘CRF Module/Guideline’ on each disorder’s data standards page. For any questions regarding these instruments/scales please contact the corresponding owner/author. The NINDS CDE Team is not responsible for the availability or content of these external sites, nor does the NINDS CDE Team endorse, warrant or guarantee the products, services or information described or offered at these other internet sites.